^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RFC4 (Replication Factor C Subunit 4)

    i
    Other names: RFC4, Replication Factor C Subunit 4, RFC37, Activator 1 37 KDa Subunit, A1 37 KDa Subunit, A1, Replication Factor C (Activator 1) 4, 37kDa, Replication Factor C 37 KDa Subunit, Activator 1 Subunit 4, RF-C 37 KDa Subunit, RFC 37 KDa Subunit, Replication Factor C (Activator 1) 4 (37kD)
    Associations

    News

    Trials
    1m
    RFC4 Promotes the Metastasis of Colorectal Cancer by Regulating the Wnt/β-Catenin Pathway. (PubMed, Cell Biol Int)
    However, the inhibitory effects of RFC4 silencing on CRC cells proliferation, migration, invasion, and EMT were partially reversed by the intervention of the Wnt/β-catenin signaling pathway activator BML-284. Altogether, these results indicate that RFC4 plays a critical role in promoting CRC metastasis, and its mechanism of action may involve the regulation of Wnt/β-catenin signaling pathway activation to facilitate EMT.
    Journal
    |
    RFC4 (Replication Factor C Subunit 4)
    1m
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    3ms
    Gene signature for response prediction to immunotherapy and prognostic markers in metastatic urothelial carcinoma. (PubMed, Front Immunol)
    From our signature, we identified key prognostic biomarkers, with the top five markers LYRM1, RFC4, CENPL, SPAG5, and CACYBP (Benjamini-Hochberg adjusted P < 0.0025) in the IMvigor210 dataset. Finally, we performed pathway analyses using Reactome (MSigDB) and KEGG, to reveal some immune-related pathways enriched such as MHC class II antigen presentation.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • RFC4 (Replication Factor C Subunit 4) • SPAG5 (Sperm Associated Antigen 5)
    3ms
    RPA1, RFC1, and POLE Expression in Clear Cell Renal Cell Carcinoma: Immune and Clinical Relevance. (PubMed, Anticancer Res)
    DNA replication proteins interact with systemic inflammation and the TME in ccRCC, supporting their role as biomarkers and potential therapeutic targets.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • POLE (DNA Polymerase Epsilon) • CD4 (CD4 Molecule) • RPA1 (Replication Protein A1) • RFC4 (Replication Factor C Subunit 4)
    4ms
    Identification of lactylation-related biomarkers in HNSC by integrating machine learning and Spatial transcriptomics analysis. (PubMed, Discov Oncol)
    MSN, KIF2C and RFC4 may serve as potential biomarkers for diagnosing and predicting the prognosis of HNSC, providing new insights into targeted therapy.
    Journal
    |
    KIF2C (Kinesin Family Member 2C) • RFC4 (Replication Factor C Subunit 4)
    4ms
    RFC4 Drives Pancreatic Cancer Progression: Prognostic Relevance and Functional Evidence. (PubMed, Anticancer Res)
    RFC4 is closely associated with pancreatic cancer progression and may serve as potential prognostic biomarker and therapeutic target for pancreatic cancer.
    Journal
    |
    RFC4 (Replication Factor C Subunit 4)
    6ms
    Construction and Validation of a Novel Prognostic Model Based on Cervical Cancer-Related Genes. (PubMed, Reprod Sci)
    APOD is a prognostic biomarker for cervical cancer, and the prognostic model constructed by identified cervical cancer-related genes can successfully distinguish the prognosis of patients with cervical cancer.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • RAD54L (DNA Repair And Recombination Protein RAD54) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • MYBL2 (MYB Proto-Oncogene Like 2) • CDC45 (Cell Division Cycle 45) • CEP55 (Centrosomal Protein 55) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • RFC4 (Replication Factor C Subunit 4) • DNA2 (DNA Replication Helicase/Nuclease 2) • SPAG5 (Sperm Associated Antigen 5)
    6ms
    Biological Role of Replication Factor C Subunit 4 in Cervical Cancer Cell Progression. (PubMed, Anticancer Res)
    RFC4 plays a key role in the progression and metastasis of cervical cancer cells and RFC4 may be an important therapeutic target in patients with cervical cancer.
    Journal
    |
    RFC4 (Replication Factor C Subunit 4)
    8ms
    Comprehensive analysis of RFC4 as a potential biomarker for regulating the immune microenvironment and predicting immune therapy response in lung adenocarcinoma. (PubMed, Front Immunol)
    RFC4 proved to be a promising biomarker for tumorigenesis and could effectively predict immunotherapy response in LUAD. RCF4 altered tumor prognosis by reshaping the TIME, and targeted inhibition of RCF4 may be a promising new strategy for treating LUAD.
    Journal • IO biomarker
    |
    RFC4 (Replication Factor C Subunit 4)
    8ms
    Roles of MARCKSL1, MCM6, RFC4, and PLAU genes in esophageal cancer and their association with radiotherapy response. (PubMed, Sci Rep)
    Additionally, the regulatory networks of these genes revealed a complex molecular regulatory mechanism, offering new perspectives for precision treatment in esophageal cancer. In summary, these genes not only offer new insights into the early diagnosis and personalized treatment of esophageal cancer but also improve patient prognosis by correlating with radiotherapy response, thus laying a solid scientific foundation for future advancements.
    Journal
    |
    MARCKS (Myristoylated Alanine Rich Protein Kinase C Substrate) • PLAU (Plasminogen Activator) • RFC4 (Replication Factor C Subunit 4) • MCM6 (Minichromosome Maintenance Complex Component 6)
    8ms
    Construction and validation of a prognostic model for glioma: an analysis based on mismatch repair-related genes and their correlation with clinicopathological features. (PubMed, Transl Cancer Res)
    In summary, our results indicate a marked elevation in EXO1 expression levels within gliomas, which correlates strongly with clinical pathological characteristics and unfavorable prognosis. Moreover, EXO1 emerges as a promising candidate biomarker and potential therapeutic target for glioma, likely playing a critical role in mediating immune infiltration within this malignancy.
    Journal • Mismatch repair
    |
    POLD1 (DNA Polymerase Delta 1) • POLD2 (DNA Polymerase Delta 2) • EXO1 (Exonuclease 1) • RFC4 (Replication Factor C Subunit 4) • RPA3 (Replication Protein A3)
    |
    IDH wild-type
    9ms
    NIP7 upregulates the expression of ubiquitin-conjugating enzyme E2 C to promote tumor growth of anaplastic thyroid cancer. (PubMed, Zhejiang Da Xue Xue Bao Yi Xue Ban)
    NIP7 promotes ATC tumor growth by upregulating UBE2C to mediate DNA replication.
    Journal
    |
    RFC4 (Replication Factor C Subunit 4) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)